Report cover image

Immunotherapy Drugs Market Growth, Size, Trends Analysis- By Type of Drug, By Therapy Area, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Publisher SPER Market Research Pvt. Ltd.
Published Oct 26, 2024
Length 245 Pages
SKU # SPER19321816

Description

Immunotherapy Drugs Market Growth, Size, Trends Analysis- By Type of Drug, By Therapy Area, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033


Immunotherapy Drugs Market Introduction and Overview

SPER Market Research in the publication titled “Global Immunotherapy Drugs Market Size – By Drug Type, Therapy Area, and End User: Regional Outlook, Competitive Strategies, and Segment Forecast to 2033,” the global market for immunotherapy drugs is projected to reach USD 674.09 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.75%.

Immunotherapy is a type of medical treatment that stimulates the immune system to attack diseases such as cancer. Immunotherapy drugs aim to improve or modify the immune system’s response to aberrant cells. Immunotherapy is used to treat cancers like melanoma, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma.

The COVID-19 outbreak has had a substantial influence on the global immunotherapy medication industry. The outbreak has caused delays in clinical trials and research, as well as disruptions in industrial and supply chain operations. The outbreak, however, has sparked interest in the use of immunotherapy drugs to treat Covid-19, resulting in increased funding and research in this field.

Scope of the Report:

Report Metric Details
Market size available for years 2020-2033
Base year considered 2023
Forecast period 2024-2033
Segments covered By Type of Drug, By Therapy Area, By End User.
Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
Companies Covered Abbott, PerkinElmer Inc, Illumina, Inc, QIAGEN, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Pfizer Inc, Sanofi, Johnson & Johnson Services, Inc, AbbVie Inc, Allergan.

Immunotherapy Drugs Market Segmentation:

By Type of Drug: Based on the Type of Drug, Global Immunotherapy Drugs Market is segmented as; Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins and Other Drugs.

By Therapy Area: Based on the Therapy Area, Global Immunotherapy Drugs Market is segmented as; Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases and Other Therapy Areas.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

245 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Immunotherapy Drugs Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Immunotherapy Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Immunotherapy Drugs Market
7. Global Immunotherapy Drugs Market, By Type of Drug USD Million) 2020-2033
7.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By Type of Drug, 2020-2026
7.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By Type of Drug, 2027-2033
7.3. Monoclonal Antibodies
7.4. Adult Vaccines
7.5. Checkpoint Inhibitors
7.6. Interferons Alpha and Beta
7.7. Interleukins
7.8. Other Drugs
8. Global Immunotherapy Drugs Market, By Therapy Area (USD Million) 2020-2033
8.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By Therapy Area, 2020-2026
8.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By Therapy Area, 2027-2033
8.3. Cancer
8.4. Autoimmune and Inflammatory Diseases
8.5. Infectious Diseases
8.6. Other Therapy Areas
9. Global Immunotherapy Drugs Market, By End User (USD Million) 2020-2033
9.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Clinics
9.5. Other End Users
10. Global Immunotherapy Drugs Market Forecast, 2020-2033 (USD Million)
10.1. Global Immunotherapy Drugs Market Size and Market Share
11. Global Immunotherapy Drugs Market, By Region, 2020-2033 (USD Million)
11.1. Global Immunotherapy Drugs Market Size and Market Share By Region (2020-2026)
11.2. Global Immunotherapy Drugs Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Abbott
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. PerkinElmer Inc
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Illumina, Inc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. QIAGEN
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. F. Hoffmann-La Roche Ltd
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Novartis AG
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. AstraZeneca
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Pfizer Inc
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Sanofi
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Johnson & Johnson Services, Inc
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. AbbVie Inc
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Allergan
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13. Others
13. Conclusion
14. List of Abbreviations
15. Reference Link

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us